Undisclosed LBP

About Siolta Therapeutics

Siolta Therapeutics is a private, clinical-stage microbiome company pioneering the development of next-generation live biotherapeutics. Its core asset is the Precision Symbiotics Platform™, which integrates clinical data, bioinformatics, and microbial science to design bacterial consortia for preventive medicine. The company's lead program, STMC-103H, has reported positive Phase 2 results for the prevention of atopic dermatitis in high-risk infants, positioning it as a potential first-in-class preventive therapy. Siolta is supported by multiple SBIR grants and is advancing a pipeline targeting atopic dermatitis, necrotizing enterocolitis, and recurrent bacterial vaginosis.

About Siolta Therapeutics

Siolta Therapeutics is a private, clinical-stage microbiome company pioneering the development of next-generation live biotherapeutics. Its core asset is the Precision Symbiotics Platform™, which integrates clinical data, bioinformatics, and microbial science to design bacterial consortia for preventive medicine. The company's lead program, STMC-103H, has reported positive Phase 2 results for the prevention of atopic dermatitis in high-risk infants, positioning it as a potential first-in-class preventive therapy. Siolta is supported by multiple SBIR grants and is advancing a pipeline targeting atopic dermatitis, necrotizing enterocolitis, and recurrent bacterial vaginosis.

Therapeutic Areas

Other Prevention of Necrotizing Enterocolitis (NEC) Drugs